LoginSignup
AC Immune logo

AC Immune Stock

StockStock
ISIN: CH0329023102
Ticker: ACIU
CH0329023102
ACIU

Price

Frequently asked questions

What is AC Immune's market capitalization?

The market capitalization of AC Immune is $302.76M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for AC Immune?

AC Immune's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.463. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for AC Immune's stock?

Currently, 4 analysts cover AC Immune's stock, with a consensus target price of $10.52. Analyst ratings provide insights into the stock's expected performance.

What is AC Immune's revenue over the trailing twelve months?

Over the trailing twelve months, AC Immune reported a revenue of $46.48M.

What is the EBITDA for AC Immune?

AC Immune's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$39.83M. EBITDA measures the company's overall financial performance.

What is the free cash flow of AC Immune?

AC Immune has a free cash flow of $48.85M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of AC Immune's stock?

The 5-year beta for AC Immune is 1.23. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does AC Immune have, and what sector and industry does it belong to?

AC Immune employs approximately 133 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of AC Immune's shares?

The free float of AC Immune is 77.34M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $302.76M

5Y beta

 1.23

EPS (TTM)

 -$0.463

Free Float

 77.34M

Revenue (TTM)

 $46.48M

EBITDA (TTM)

 -$39.83M

Free Cashflow (TTM)

 $48.85M

Pricing

1D span
$3.02$3.231
52W span
$2.25$5.14

Analyst Ratings

The price target is $10.52 and the stock is covered by 4 analysts.

Buy

4

Hold

0

Sell

0

Information

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

133

Biotechnology & Drugs

Health Care

Identifier

ISIN

CH0329023102

Primary Ticker

ACIU

Knockouts

Join the conversation
Sign upLogin